JP2024038524A5 - - Google Patents

Download PDF

Info

Publication number
JP2024038524A5
JP2024038524A5 JP2024016033A JP2024016033A JP2024038524A5 JP 2024038524 A5 JP2024038524 A5 JP 2024038524A5 JP 2024016033 A JP2024016033 A JP 2024016033A JP 2024016033 A JP2024016033 A JP 2024016033A JP 2024038524 A5 JP2024038524 A5 JP 2024038524A5
Authority
JP
Japan
Prior art keywords
sulfate
peaks
dihydrogen phosphate
disease
sulfate form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024016033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024038524A (ja
JP7758768B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/027369 external-priority patent/WO2019200345A1/en
Application filed filed Critical
Publication of JP2024038524A publication Critical patent/JP2024038524A/ja
Publication of JP2024038524A5 publication Critical patent/JP2024038524A5/ja
Priority to JP2025105737A priority Critical patent/JP2025131907A/ja
Priority to JP2025171096A priority patent/JP2026004574A/ja
Application granted granted Critical
Publication of JP7758768B2 publication Critical patent/JP7758768B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024016033A 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法 Active JP7758768B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025105737A JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862656435P 2018-04-12 2018-04-12
US62/656,435 2018-04-12
PCT/US2019/027369 WO2019200345A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof
JP2020555811A JP7532718B2 (ja) 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020555811A Division JP7532718B2 (ja) 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025105737A Division JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A Division JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2024038524A JP2024038524A (ja) 2024-03-19
JP2024038524A5 true JP2024038524A5 (cg-RX-API-DMAC7.html) 2025-01-21
JP7758768B2 JP7758768B2 (ja) 2025-10-22

Family

ID=68163817

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555811A Active JP7532718B2 (ja) 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2024016033A Active JP7758768B2 (ja) 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025105737A Pending JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A Pending JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020555811A Active JP7532718B2 (ja) 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025105737A Pending JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A Pending JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Country Status (7)

Country Link
US (3) US11498908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773531A4 (cg-RX-API-DMAC7.html)
JP (4) JP7532718B2 (cg-RX-API-DMAC7.html)
CN (1) CN112105349A (cg-RX-API-DMAC7.html)
AU (2) AU2019253028B2 (cg-RX-API-DMAC7.html)
CA (2) CA3096671C (cg-RX-API-DMAC7.html)
WO (1) WO2019200345A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
JP2025514292A (ja) * 2022-04-29 2025-05-02 ▲蘇▼州科睿思制▲葯▼有限公司 塩酸ブラルカメシンの結晶形、その調製方法およびその使用
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
GR1008233B (el) * 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
EP4616852A3 (en) * 2015-07-22 2025-10-22 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法

Similar Documents

Publication Publication Date Title
TWI689490B (zh) 用於治療纖維化之經取代之芳族化合物及相關方法
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2003507438A5 (cg-RX-API-DMAC7.html)
US8426388B2 (en) Prodrugs of HIV protease inhibitors
TW200811167A (en) Modulators of pharmacokinetic properties of therapeutics
JP2022543244A5 (cg-RX-API-DMAC7.html)
JP2023552700A5 (cg-RX-API-DMAC7.html)
JP6959246B2 (ja) 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒
JP2025118775A5 (cg-RX-API-DMAC7.html)
JP2004026678A (ja) 2型糖尿病治療剤
JP2002544227A5 (cg-RX-API-DMAC7.html)
WO2002034245A2 (en) Use of tolterodine to treat asthma
JP2023505587A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
JP2023505598A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
JP2022501364A5 (cg-RX-API-DMAC7.html)
JP2023538419A5 (cg-RX-API-DMAC7.html)
CN111909204B (zh) 一种替诺福韦双苯丙酸酯基氨基磷酸酯化合物及其药物组合物和用途
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
WO2024192149A3 (en) Method of treating enterovirus in chronic obstructive pulmonary disease patients
US12344619B2 (en) Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN102659570A (zh) 二氟非诺贝特酸及其在药学上可接受的盐,以及它们的制备方法和应用
JP2023512023A5 (cg-RX-API-DMAC7.html)
JP2024541770A5 (cg-RX-API-DMAC7.html)
AU2024203992B2 (en) Prophylactic or therapeutic agent for porphyria
JP2000219626A (ja) ケロイドおよび/または肥厚性瘢痕の治療剤